Literature DB >> 3036427

Proton magnetic resonance imaging to stage activity of interstitial lung disease.

R G McFadden, T J Carr, T E Wood.   

Abstract

Patients with active interstitial lung disease (ILD) are often treated with high-dose corticosteroids, although such therapy is not universally effective and has significant risks. Clinicians have utilized various ancillary diagnostic techniques to help with difficult treatment decisions. Since magnetic resonance imaging (MRI) has the theoretic and experimental potential of differentiating various stages of ILD, we prospectively studied 34 adult patients in a 0.15 Tesla resistive magnet body imager. The most severely affected patients, who were thought to warrant a steroid trial, had the greatest MRI image intensity, and dramatic improvement was seen following successful treatment. Qualitative MRI data were as useful as any other ancillary diagnostic technique (radiographic, physiologic, scintigraphic) in predicting clinical course. Computer-generated relaxation times were not sufficiently precise to differentiate active from inactive disease. Although limited by availability and cost, MRI appears to be a useful ancillary diagnostic technique in ILD patients facing immunomodulating therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036427     DOI: 10.1378/chest.92.1.31

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis.

Authors:  Iago Pinal-Fernandez; Victor Pineda-Sanchez; Esther Pallisa-Nuñez; Carmen Pilar Simeon-Aznar; Albert Selva-O'Callaghan; Vicente Fonollosa-Pla; Miquel Vilardell-Tarres
Journal:  Clin Rheumatol       Date:  2016-04-23       Impact factor: 2.980

2.  T2 mapping of CT remodelling patterns in interstitial lung disease.

Authors:  Maria T A Buzan; Monika Eichinger; Michael Kreuter; Hans-Ulrich Kauczor; Felix J Herth; Arne Warth; Carmen Monica Pop; Claus Peter Heussel; Julien Dinkel
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

3.  High-resolution computed tomography and magnetic resonance imaging protocols in the diagnosis of fibrotic interstitial lung disease: overview for "non-radiologists".

Authors:  Gianluigi Sergiacomi; Luca Pugliese; Francesca Ricci; Roberto Floris; Armando Fusco
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

4.  Lung MRI at 3.0 T: a comparison of helical CT and high-field MRI in the detection of diffuse lung disease.

Authors:  G Lutterbey; J Gieseke; M von Falkenhausen; N Morakkabati; H Schild
Journal:  Eur Radiol       Date:  2004-11-23       Impact factor: 5.315

5.  [MRI of interstitial lung diseases: what is possible?].

Authors:  J Biederer; M O Wielpütz; B J Jobst; J Dinkel
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

6.  Lung disease assessment in primary ciliary dyskinesia: a comparison between chest high-field magnetic resonance imaging and high-resolution computed tomography findings.

Authors:  Silvia Montella; Francesca Santamaria; Marco Salvatore; Marco Maglione; Paola Iacotucci; Maria Margherita De Santi; Carmine Mollica
Journal:  Ital J Pediatr       Date:  2009-08-06       Impact factor: 2.638

7.  Delayed contrast dynamics as marker of regional impairment in pulmonary fibrosis using 5D MRI - a pilot study.

Authors:  Maria Ta Buzan; Andreas Wetscherek; Christopher M Rank; Michael Kreuter; Claus Peter Heussel; Marc Kachelrieß; Julien Dinkel
Journal:  Br J Radiol       Date:  2020-07-08       Impact factor: 3.039

8.  MRI of the lung (3/3)-current applications and future perspectives.

Authors:  Jürgen Biederer; S Mirsadraee; M Beer; F Molinari; C Hintze; G Bauman; M Both; E J R Van Beek; J Wild; M Puderbach
Journal:  Insights Imaging       Date:  2012-01-15

9.  Texture analysis using proton density and T2 relaxation in patients with histological usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP).

Authors:  Maria T A Buzan; Andreas Wetscherek; Claus Peter Heussel; Michael Kreuter; Felix J Herth; Arne Warth; Hans-Ulrich Kauczor; Carmen Monica Pop; Julien Dinkel
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.